Teva reviews robust Q2 outcomes, raises 2024 forecast
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) reported robust outcomes for the second quarter of 2024 and once ...
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) reported robust outcomes for the second quarter of 2024 and once ...
JLGutierrez Here’s a company with one approved product in one rare disease, another product just approved and about to be ...
After just over a year in the job, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) CEO Richard Francis ...
© Sivan Farag, Teva PR TEL AVIV - In the latest market movements on the Tel Aviv Stock Exchange, key ...
Dr_Microbe/iStock via Getty Images Corcept Therapeutics (NASDAQ:CORT) plummeted 38% in after-hours trading on Friday after a loss in a patent ...
Israeli drug developer Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) and French pharmaceutical company Sanofi (Nasdaq: SNY; Euronext: ...
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) today announced the conclusion of a full resolution on its US ...
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) today reported results for the quarter ended September 30, 2022. Revenue for ...
Shareholders in Teva Pharmaceutical Industries (TASE: TEVA; NYSE: TEVA) filed four petitions for discovery of documents in the Tel Aviv ...
© Reuters. FILE PHOTO: The CEO of Teva Pharmaceutical Industries Kare Schultz speaks during a news conference to discuss the ...
Copyright © 2022 - Index Investing News.
Index Investing News is not responsible for the content of external sites.